Trial Profile

Assessment of clinical efficacy and safety in capecitabine plus intermittent oxaliplatin (intermittent CapeOx) together with Bevacizumab as the first-line therapy for patients with advanced colorectal cancer; multicenter phase II trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms VOICE

20 Jan 2018 Status changed from recruiting to completed, according to the results presented at the 2018 Gastrointestinal Cancers Symposium
20 Jan 2018 Primary endpoint (Progression free survival) has been met. according to the results presented at the 2018 Gastrointestinal Cancers Symposium
20 Jan 2018 Final results presented at the 2018 Gastrointestinal Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com